1. Home
  2. GTEC vs INTS Comparison

GTEC vs INTS Comparison

Compare GTEC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

N/A

Current Price

$0.74

Market Cap

21.9M

Sector

Industrials

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

N/A

Current Price

$7.71

Market Cap

19.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GTEC
INTS
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.9M
19.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GTEC
INTS
Price
$0.74
$7.71
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$56.25
AVG Volume (30 Days)
143.6K
866.4K
Earning Date
01-01-0001
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.64
N/A
Revenue Next Year
$3.93
N/A
P/E Ratio
$1.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$0.19
52 Week High
$2.58
$8.06

Technical Indicators

Market Signals
Indicator
GTEC
INTS
Relative Strength Index (RSI) 42.60 83.05
Support Level $0.66 $0.29
Resistance Level $1.16 $8.06
Average True Range (ATR) 0.06 0.59
MACD 0.00 0.18
Stochastic Oscillator 27.29 95.34

Price Performance

Historical Comparison
GTEC
INTS

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: